EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review

Ran Lu iD, Ye Liu iD, Tianpei Hong iD

Diabetes, Obesity and Metabolism · 2023-04 · 25 (S1) · 13-26

DOI: 10.1111/dom.15014 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 28.02.2023. Verfasst von Ran Lu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 96 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

With industrialization and spread of the westernized lifestyle, the number of people affected by non‐alcoholic fatty liver disease (NAFLD)/non‐alcoholic steatohepatitis (NASH) is growing rapidly in China; this has become a major public health concern. To better understand the burden and characteristics of NAFLD/NASH in China, we aim to perform a narrative review of the literature published in this field. Materials and Methods We carried out a comprehensive electronic search of five English‐language and three Chinese‐language databases, to identify studies regarding NAFLD or NASH published from inception to November 30, 2022. Epidemiological studies of NAFLD/NASH in China were particularly noticed and summarized. We also searched the www.clinicaltrials.gov and www.chictr.org.cn websites for the registered trials on the treatment of the disease led by Chinese investigators or located in China.

Results

The increasing rate of NAFLD prevalence in China is strikingly high, reaching more than twice that in western countries. The prevalence of NAFLD is nearly 30% of the general Chinese population, making it the leading cause of chronic liver diseases. The prevalence of NAFLD/NASH varies between provinces/regions, age groups, sexes, and individuals with different metabolic profiles. NAFLD co‐exists in many Chinese patients with chronic hepatitis B. Since 2020, more Chinese studies have used the term metabolic‐associated fatty liver disease (MAFLD), emphasizing the underlying metabolic disorders that occur concurrently with this disease. Several clinical trials involving lifestyle interventions, antidiabetic drugs, or traditional Chinese medicines, registered by Chinese investigators, have been completed or are ongoing. Moreover, several innovative targeted therapies developed in China are revolutionizing the treatment of NAFLD/NASH.

Conclusions

NAFLD has cast a heavy burden on the Chinese healthcare system. Chinese scholars are making efforts to achieve the optimal management of this disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseHumansHypoglycemic AgentsChina

Stichwörter der Autor:innen

clinical trialcohort studyfatty liver diseaseobservational studytype 2 diabetes mellitusweight control

Substanzen

Hypoglycemic Agents

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Peking University Third Hospital, Beijing, China.

ORCID-Profile: Ran Lu, Ye Liu, Tianpei Hong

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Lu, R., Liu, Y., & Hong, T. (2023). Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review. Diabetes, Obesity and Metabolism, 25(S1), 13-26. https://doi.org/10.1111/dom.15014

Vancouver

Lu R, Liu Y, Hong T. Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review. Diabetes, Obesity and Metabolism. 2023;25(S1):13-26. doi:10.1111/dom.15014

BibTeX
@article{Lu2023,
  author = {Lu, Ran and Liu, Ye and Hong, Tianpei},
  title = {Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  volume = {25},
  number = {S1},
  pages = {13--26},
  doi = {10.1111/dom.15014}
}
Kostenlos starten →